Logo

American Heart Association

  113
  0


Final ID: MDP469

Traditional Risk Factors, Cardiovascular Health, and Elevated Lipoprotein(a): The Multi-Ethnic Study of Atherosclerosis

Abstract Body (Do not enter title and authors here): Introduction: One in five individuals have elevated lipoprotein(a) [Lp(a)], an inheritable risk factor that is causally associated with atherosclerotic cardiovascular disease (ASCVD). Whether individuals with elevated Lp(a) derive similar benefit from control of ASCVD risk factors has not been well-studied.

Hypothesis: The magnitude of benefit associated with optimal cardiovascular health will be similar across the spectrum of Lp(a).

Aim: To assess the association of traditional risk factor burden and Life’s Simple 7 (LS7) score with incident ASCVD across Lp(a) values.

Methods: We studied 6,676 participants from the Multi-Ethnic Study of Atherosclerosis who underwent Lp(a) testing and were followed for incident ASCVD events (coronary heart disease and stroke). Elevated Lp(a) was defined as >50 mg/dL. As defined by the American Heart Association, LS7 metrics included smoking, physical activity, body mass index, diet, total cholesterol, blood pressure, and glucose. Multivariable Cox proportional hazards regression assessed the association of traditional risk factor burden and LS7 score (poor: 0-8, average: 9-10, optimal: 11-14) with incident ASCVD for individuals with and without elevated Lp(a) during a median follow-up of 17.7 years.

Results: The mean age was 62.1 years, 53% were women, and 61% were non-white. The median Lp(a) was 17 mg/dL and 20% had Lp(a) >50 mg/dL. Individuals with Lp(a) >50 mg/dL had the highest burden of traditional risk factors except cigarette smoking. Compared to those with a poor LS7 score, those with an optimal LS7 score had a lower ASCVD risk that was significant for participants with Lp(a) <50 mg/dL (HR=0.37, 95% CI: 0.25-0.55), but borderline significant for participants with Lp(a) >50 mg/dL (HR=0.41, 95% CI: 0.16-1.02). Individuals with Lp(a) >50 mg/dL had the highest absolute event rates across all LS7 categories, and there was no significant interaction between Lp(a) and LS7 score on incident ASCVD (p-interaction=0.64, Figure).

Conclusions: Participants with an optimal LS7 score had similar reduction in ASCVD risk regardless of their Lp(a) burden. These results emphasize the importance of a healthy lifestyle and ASCVD risk factor control among patients with elevated Lp(a).
  • Razavi, Alexander  ( Emory University , Atlanta , Georgia , United States )
  • Reyes, Mikaila  ( University of California San Diego , La Jolla , California , United States )
  • Wilkins, John  ( Northwestern University , Chicago , Illinois , United States )
  • Szklo, Moyses  ( JOHNS HOPKINS UNIV , Baltimore , Maryland , United States )
  • Tsai, Michael  ( UNIVERSITY MINNESOTA , Minneapolis , Minnesota , United States )
  • Whelton, Seamus  ( Johns Hopkins , Baltimore , Maryland , United States )
  • Sperling, Laurence  ( EMORY UNIV , Atlanta , Georgia , United States )
  • Tsimikas, Sotirios  ( UNIV CALIFORNIA SAN DIEGO , La Jolla , California , United States )
  • Bhatia, Harpreet  ( University of California San Diego , San Diego , California , United States )
  • Author Disclosures:
    Alexander Razavi: DO NOT have relevant financial relationships | Mikaila Reyes: DO NOT have relevant financial relationships | John Wilkins: DO NOT have relevant financial relationships | Moyses Szklo: No Answer | Michael Tsai: DO NOT have relevant financial relationships | Seamus Whelton: DO NOT have relevant financial relationships | Laurence Sperling: DO NOT have relevant financial relationships | Sotirios Tsimikas: DO have relevant financial relationships ; Royalties/Patent Beneficiary:UCSd:Active (exists now) ; Employee:Ionis:Active (exists now) ; Consultant:Novartis:Active (exists now) ; Ownership Interest:Oxitope:Active (exists now) ; Ownership Interest:Kleanthi:Active (exists now) | Harpreet Bhatia: DO have relevant financial relationships ; Consultant:Kaneka:Past (completed) ; Advisor:Arrowhead:Active (exists now) ; Advisor:Abbott:Active (exists now) ; Advisor:Novartis:Active (exists now) ; Consultant:Novartis:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Lipids and Management - A Deep Dive

Saturday, 11/16/2024 , 11:10AM - 12:35PM

Moderated Digital Poster Session

More abstracts on this topic:
A Multicenter Study of Detection of Pulmonary Hypertension Based on Point-of-Care 12- Lead ECG Data

Dubrock Hilary, Wieczorek Mikolaj, Hackett Sarah, Alger Heather, Carlson Katherine, Klugherz Paul, Carter Rickey, Wagner Tyler, Johnson Patrick, Frantz Robert, Strom Jordan, Waks Jonathan, Agarwal Richa, Hemnes Anna, Steinberg Benjamin, Pandey Ambarish

A Randomized Phase 2 Trial of Muvalaplin: An Oral Disrupter of the Assembly of Lipoprotein(a) Particles

Nicholls Stephen, Ni Wei, Rhodes Grace, Nissen Steven, Navar Ann Marie, Michael Laura, Krege John

More abstracts from these authors:
Long-Term Cumulative LDL-C Exposure and ASCVD Events in Young Adults with CAC=0: Insights from the CARDIA Study

Peng Allison, Blaha Michael, Blumenthal Roger, Gianos Eugenia, Razavi Alexander, Bimal Tia, Rubin Maya, Allen Norrina, Wilkins John, Sperling Laurence, Rana Jamal, Whelton Seamus

Association of Lipoprotein(a) and Interleukin-6 with Cardiovascular Risk: the Multi-Ethnic Study of Atherosclerosis and UK Biobank

Bhatia Harpreet, Mcparland James, Rikhi Rishi, Tsai Michael, Szklo Moyses, Tsimikas Sotirios, Yeang Calvin, Shapiro Michael

You have to be authorized to contact abstract author. Please, Login
Not Available